| | Scope | Document part | Language | Document |
|---|
| GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 1 Part 2 6. | HM | Schedule 1
Part 2
6. | EN | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| ICH ICH E6 Guideline R3 (2025) Appendix B 12.3 | G | Appendix B
12.3 | EN | ICH ICH E6 Guideline R3 (2025) |
| ICH ICH E6 Guideline R3 (2025) Appendix B 2.5 | G | Appendix B
2.5 | EN | ICH ICH E6 Guideline R3 (2025) |
| ICH ICH E6 Guideline R3 (2025) GLOSSARY - Compliance (in relation to trials) | G | GLOSSARY - Compliance (in relation to trials) | EN | ICH ICH E6 Guideline R3 (2025) |
| ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.5 | G | III. Annex 1
2.5 | EN | ICH ICH E6 Guideline R3 (2025) |
| ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.12 | G | III. Annex 1
3.12 | EN | ICH ICH E6 Guideline R3 (2025) |
| ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 10.6 | MD | 10.6 | EN | ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 |
| USA 21 CFR Part 812 09-Apr-2025 § 812.110 (b) | MD | § 812.110
(b) | EN | USA 21 CFR Part 812 09-Apr-2025 |
| USA 21 CFR Part 812 09-Apr-2025 § 812.30 (b) - (c) | MD | § 812.30
(b) - (c) | EN | USA 21 CFR Part 812 09-Apr-2025 |
| USA 21 CFR Part 812 09-Apr-2025 § 812.46 (a) | MD | § 812.46
(a) | EN | USA 21 CFR Part 812 09-Apr-2025 |
| USA 45 CFR Part 46 09-Apr-2025 Subpart E | G | Subpart E | EN | USA 45 CFR Part 46 09-Apr-2025 |
| WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.4 - Introduction | HM | 4.4 - Introduction | EN | WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 |
